Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
The U.S. Food and Drug Administration (FDA) has approved a label update to Novartis’ Cosentyx (secukinumab), doubling the previously recommended dose to 300 mg for adults with active ankylosing ... Read more
People with ankylosing spondylitis (AS) are almost three times more likely to develop obstructive sleep apnea (OSA) than healthy individuals, a population-based study in Taiwan shows. The risk is ... Read more
Qletli, a biosimilar to Humira (adalimumab), is now available in China for the treatment of three autoimmune diseases, including ankylosing spondylitis (AS). The medication is also approved for the ... Read more
Despite experiencing similar symptoms, people with non-radiographic axial spondyloarthritis (nr-axSpA) are less likely to be treated with a biologic therapy than those with ankylosing spondylitis (AS), according to a ... Read more
The first ankylosing spondylitis (AS) patient has been dosed in a Phase 3 trial testing SCB-808, a potential biosimilar of Enbrel (etanercept) being developed for the treatment of rheumatic diseases in ... Read more
LINC00311, a type of long non-coding RNA molecule, is overexpressed in patients with ankylosing spondylitis and is associated with worse treatment outcomes and higher likelihood of disease recurrence, a ... Read more
Overall, patients with ankylosing spondylitis (AS) are more likely to develop osteoporosis compared to the general population, a new study shows. However, the risk is particularly high for AS ... Read more